The mTOR inhibitor everolimus has shown an ORR of 44% and a complete response (CR) of 6.3%, with a median PFS of 4.1 months in R/R PTCL patients (11). The gene discussed is MTOR; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.